Bioqual (OTCMKTS:BIOQ – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.56) EPS for the quarter, Zacks reports. Bioqual had a negative net margin of 9.75% and a negative return on equity of 11.20%. The company had revenue of $10.15 million for the quarter.
Bioqual Stock Performance
Bioqual stock opened at $30.64 on Friday. The company has a market cap of $27.27 million, a price-to-earnings ratio of -7.03 and a beta of -0.10. The firm has a 50 day moving average price of $32.83 and a 200 day moving average price of $33.65. Bioqual has a 1 year low of $30.64 and a 1 year high of $43.55.
Bioqual Company Profile
Bioqual, Inc is a biomedical research and contract research organization based in Rockville, Maryland. The company provides preclinical research services to pharmaceutical and biotechnology companies, government agencies, and other organizations involved in the development of medical products.
Its work focuses primarily on infectious diseases, vaccines, therapeutics, and diagnostics. Bioqual conducts laboratory and animal-model studies designed to evaluate the safety, efficacy, immunology, virology, and pharmacology of potential treatments and preventive products.
Read More
- Five stocks we like better than Bioqual
- NextEra and Dominion Have a Deal—Now Comes the Hard Part
- Microsoft’s Earnings Problem: Even Great May Not Be Enough
- 3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
- Is Texas Instruments Setting Up for Its Next Big Breakout?
Receive News & Ratings for Bioqual Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioqual and related companies with MarketBeat.com's FREE daily email newsletter.
